Micromet to Present at the UBS Global Life Sciences Conference on September 22, 2009
September 16 2009 - 11:00AM
PR Newswire (US)
BETHESDA, Md., Sept. 16 /PRNewswire-FirstCall/ -- Micromet, Inc.
(NASDAQ: MITI), a biopharmaceutical company developing novel,
proprietary antibodies for the treatment of cancer, inflammation
and autoimmune diseases, today announced that its President and
CEO, Dr. Christian Itin, will present at the UBS Global Life
Sciences Conference on September 22, 2009 in New York City. A
simultaneous webcast of the event will be available on the
company's website at http://www.micromet-inc.com/. Forum: UBS
Global Life Sciences Conference Date: Tuesday, September 22, 2009
Time: 8:00 am to 8:30 am U.S. Eastern Time Place: Grand Hyatt New
York New York City, New York Webcast: http://www.micromet-inc.com/
About Micromet, Inc. Micromet, Inc. is a biopharmaceutical company
developing novel, proprietary antibodies for the treatment of
cancer, inflammation and autoimmune diseases. Its product
development pipeline includes novel antibodies generated with its
proprietary BiTE antibody platform, as well as conventional
monoclonal antibodies. Two of Micromet's BiTE antibodies and three
of its conventional antibodies are currently in clinical trials.
Micromet's preclinical product pipeline includes several novel BiTE
antibodies generated with its proprietary BiTE antibody platform
technology. Micromet's collaboration partners include Bayer
Schering Pharma, Merck Serono, MedImmune and Nycomed.
Forward-Looking Statements This release contains certain
forward-looking statements that involve risks and uncertainties
that could cause actual results to be materially different from
historical results or from any future results expressed or implied
by such forward-looking statements. These forward-looking
statements include statements regarding the efficacy, safety and
intended utilization of blinatumomab and other product candidates,
the conduct, timing and results of future clinical trials, and
expectations of the future expansion of our product pipeline and
collaborations. You are urged to consider statements that include
the words "ongoing," "may," "will," "believes," "potential,"
"expects," "plans," "anticipates," "intends," or the negative of
those words or other similar words to be uncertain and
forward-looking. Factors that may cause actual results to differ
materially from any future results expressed or implied by any
forward-looking statements include the risk that product candidates
that appeared promising in early research, preclinical studies or
clinical trials do not demonstrate safety and/or efficacy in
subsequent clinical trials, the risk that encouraging results from
early research, preclinical studies or clinical trials may not be
confirmed upon further analysis of the detailed results of such
research, preclinical study or clinical trial, the risk that
additional information relating to the safety, efficacy or
tolerability of our product candidates may be discovered upon
further analysis of preclinical or clinical trial data, the risk
that we or our collaborators will not obtain approval to market our
product candidates, the risks associated with reliance on outside
financing to meet capital requirements, and the risks associated
with reliance on collaborators, including MedImmune, Merck Serono,
TRACON and Nycomed, for the funding or conduct of further
development and commercialization activities relating to our
product candidates. These factors and others are more fully
discussed in Micromet's Quarterly Report on Form 10-Q for the
fiscal quarter ended June 30, 2009, filed with the SEC on August 6,
2009, as well as other filings by the company with the SEC.
DATASOURCE: Micromet, Inc. CONTACT: US Media: Andrea tenBroek, or
Chris Stamm, +1-781-684-0770, ; European Media: Ludger Wess, +49
(40) 8816 5964, ; US Investors: Susan Noonan, +1-212-966-3650, ; or
European Investors: Ines-Regina Buth, +49 (30) 2363 2768, Web Site:
http://www.micromet-inc.com/
Copyright